Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody

Bryony Treston,Sarah Geoghegan

DOI: https://doi.org/10.1080/21645515.2024.2341505

2024-05-11

Human Vaccines & Immunotherapeutics

Abstract:Respiratory Syncytial Virus poses a significant global public health threat, particularly affecting infants aged less than one year of age. Recently, two forms of passive immunization against infant RSV have been developed and brought to market; nirsevimab a long-acting monoclonal antibody (mAb) and RSV-PreF, a maternal RSV vaccine. The acceptability and uptake of these products will play a pivotal role in determining the success of any national immunization strategy aimed at safeguarding infants from RSV. It is crucial at this time to reflect on the factors that influence parental decisions surrounding immunization to facilitate more informed discussions, enhance healthcare communication, and contribute to the design of effective RSV prevention strategies that resonate with the concerns and aspirations of parents worldwide.

immunology,biotechnology & applied microbiology

What problem does this paper attempt to address?

The paper primarily explores the acceptance and usage of two preventive strategies against respiratory syncytial virus (RSV) — maternal vaccine (RSVpreF) and infant monoclonal antibody (nirsevimab) — in practical applications. RSV poses a significant threat to infants under 1 year old, leading to a large number of hospitalizations and deaths globally each year. Currently, two passive immunization products have been developed and marketed: one is the long-acting monoclonal antibody nirsevimab, and the other is the maternal vaccine RSVpreF. The acceptance of these two products will directly impact the success of any national immunization strategy aimed at protecting infants from RSV.

The paper focuses on the following aspects:
1. **Safety**: Safety is a key factor influencing whether pregnant women and parents accept these new products. Studies indicate that although clinical trials show both products have good tolerability, the safety of new vaccines or drugs remains a major public concern.
2. **Efficacy**: While efficacy is also an important consideration, multiple surveys suggest that women seem to be more concerned about the safety of the product rather than its efficacy.
3. **Healthcare Provider Recommendation**: Pregnant women and parents tend to rely on healthcare providers' recommendations to decide whether to vaccinate or use monoclonal antibodies.
4. **Disease Awareness**: Low awareness of RSV may affect vaccine acceptance. Increasing public awareness of the severity of RSV can help boost vaccination rates.
5. **Situation in Low- and Middle-Income Countries**: In resource-limited settings, choosing more cost-effective immunization strategies is particularly important. The maternal vaccine, being less expensive, may be more feasible in these regions.

In summary, the paper aims to provide a basis for designing more effective RSV prevention strategies by analyzing various factors that influence parental decision-making, thereby better addressing the health challenges posed by RSV globally.